In addition, a humanized anti-human GPC3 antibody, GC33, was tested in clinical trials to examine the pharmacokinetics, dosage and duration of treatment, safety and tolerability, and antitumor activity in GPC3 high expression hepatoma cells (Tables 4, 5). The gene discussed is GPC3; the disease is hepatocellular carcinoma.